<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200612047740N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-06-18</date_registration>
      <primary_sponsor>Artesh University of Medical Sciences</primary_sponsor>
      <public_title>The effect of esophageal pressure measurement to prevent pulmonary barotrauma in patients with Covid 19 undergoing respiratory support</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of esophageal pressure measurement for non-invasive positive pressure ventilation (NIPPV) regulation for the prevention of pulmonary barotrauma in comparison with control group in patients with Covid 19 undergoing respiratory support admitted to the intensive care unit</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60038</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly assigned to the groups of A and B using Randomization software (https://www.randomizer.org/) according to inclusion criteria. Each group has 45 members. In this software, numbers from 1 to 90 are entered into the software and at one time, they randomly pick the numbers from one to ninety so that the number of people in each group is equal. The numbers remain hidden and the order in which people enter the study is revealed in the order in which the data output software is displayed, and if the number is between 1 and 45, it is placed in the first group and if it is between 46 and 90, it is placed in the second group, Blinding description: Patients are divided into two groups A and B and are kept in two separate parts. How to do the study for each group is described. The information is collected by the clinical caregiver and the researcher and data analyzer do not know the patient group and after analyzing the data, the codes are decoded to avoid bias.</study_design>
      <phase>3</phase>
      <hc_freetext>COVID-19.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients's nasogastric tube is pulled up and connected to a manometer and their intraesophageal pressure is measured. Ventilation settings are adjusted so that the difference in pulmonary pressure remains between 0-10 cm of water and if it is more than 35 to 40 cm of water, the settings of the device are reduced and no trauma occurs. Finally, the incidence of barotrauma in this group is measured. Intervention 2: Control group: Patients in this group do not have daily intraesophageal pressure measurements. Ventilation settings of patients in this group are controlled through anesthesia instructions set by the anesthesiologist (project manager) and the incidence of barotrauma in this group is measured.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only registered symptoms can be published without mentioning the names of the participants

When:
Start of access period 6 months after printing the results up to one year after printing

To whom:
Only available to scholars working in academia and academia

Conditions:
Written request via email(hossein.naderi1374@gmail.com) and university approval

Where to obtain:
By contacting the corresponding author

How to obtain:
After the email is received by the applicant, it takes one week to agree The university will be obtained and then will be notified to the requestor. Maximum of this process takes ten days.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hossein Naderi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>AJA University of medical sciences, Shahid Etemadzade st, West Fatemi</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411718541</zip>
        <telephone>+98 21 8609 6350</telephone>
        <email>hossein.naderi1374@gmail.com</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hossein Naderi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>AJA University Of Medical Sciences, Shahid Etemadzade st, West Fatemi</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411718541</zip>
        <telephone>+98 31 3568 5233</telephone>
        <email>hossein.naderi1374@gmail.com</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with Covid 19 with positive PCR or CT scan
Hospitalized in the intensive care unit
Patient is receiving non-mechanical ventilation
Patient should be fed through the gastric feeding tube (NG tube)
Informed consent of the patient or his legal guardian</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Coagulation disorders
Gastrointestinal bleeding
History of fractures and trauma to the base of the skull</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>U.07</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>COVID-19 Disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients's nasogastric tube is pulled up and connected to a manometer and their intraesophageal pressure is measured. Ventilation settings are adjusted so that the difference in pulmonary pressure remains between 0-10 cm of water and if it is more than 35 to 40 cm of water, the settings of the device are reduced and no trauma occurs. Finally, the incidence of barotrauma in this group is measured.</i_keyword>
      <i_keyword>Control group: Patients in this group do not have daily intraesophageal pressure measurements. Ventilation settings of patients in this group are controlled through anesthesia instructions set by the anesthesiologist (project manager) and the incidence of barotrauma in this group is measured.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intra esophageal pressure. Timepoint: Intraesophageal pressure is measured twice daily (morning and evening) while receiving non-invasive ventilation while the patient is in the intensive care unit(ICU). Method of measurement: Manometer.</prim_outcome>
      <prim_outcome>Number of people with barotrauma. Timepoint: From the start of non-invasive ventilation to the onset of barotrauma. Method of measurement: Observe and record.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Oxygen saturation. Timepoint: It is measured twice daily (morning and evening) while receiving non-invasive ventilation while the patient is in the intensive care unit(ICU). Method of measurement: Pulse oximeter.</sec_outcome>
      <sec_outcome>Duration of stay in the intensive care unit. Timepoint: From the time of entering the intensive care unit until the time of discharge or the time of death. Method of measurement: Observe and record.</sec_outcome>
      <sec_outcome>Trans pulmonary pressure. Timepoint: Trans pulmonary pressure is measured twice daily (morning and evening) while receiving non-invasive ventilation while the patient is in the ICU. Method of measurement: Manometer.</sec_outcome>
      <sec_outcome>Time of barotrauma. Timepoint: Number of days from the start of non-invasive ventilation to the onset of barotrauma. Method of measurement: Observe and record.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Artesh University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-02-20</approval_date>
        <contact_name>Ethics committee of AJA University of Medical</contact_name>
        <contact_address>AJA university of medical sciences, Shahid Etemadzade st, West Fatemi st Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
